Search
RTA 744
go.drugbank.com/drugs/DB05920InvestigationalRTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.
MUC1 Dendritic Cell Vaccine
go.drugbank.com/drugs/DB05477InvestigationalThe Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
PN0621
go.drugbank.com/drugs/DB05218ExperimentalIt is being developed by Peptech. … PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.
ACR-16
go.drugbank.com/drugs/DB05371InvestigationalACR-16 is under investigation by NeuroSearch. … ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.
SR-123781A
go.drugbank.com/drugs/DB05361InvestigationalSR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
TA-CIN
go.drugbank.com/drugs/DB05809InvestigationalTA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. … NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.
MD-0727
go.drugbank.com/drugs/DB05948InvestigationalMD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.